文献速递免疫规划

假结核棒状杆菌重组蛋白rCP09720或rCP01850与rPLD联合作为免疫原在干酪性淋巴结炎免疫预防中的关联研究

Association of Corynebacterium pseudotuberculosis recombinant proteins rCP09720 or rCP01850 with rPLD as immunogens in caseous lymphadenitis immunoprophylaxis.
PubMed 文献 · Vaccine · 2017-11-22

本研究在小鼠中评价假结核棒状杆菌重组蛋白rCP09720或rCP01850与重组外毒素磷脂酶D(rPLD)联合作为亚单位疫苗的效果。四个实验组每组10只小鼠,分别免疫生理盐水、rPLD、rPLD+rCP09720、rPLD+rCP01850,间隔21天两次免疫,末次免疫后21天攻毒,攻毒后观察40天。rPLD+rCP01850组生存率50%,诱导最强的1型辅助T细胞免疫应答,为最佳保护组合。

要点

  • rPLD+rCP01850组攻毒后生存率50%,高于rPLD组30%和rPLD+rCP09720组40%。
  • rPLD+rCP01850组对两种抗原均产生显著(p<.05)体液免疫应答。
  • 各免疫组干扰素-γ产量显著(p<.05)高于对照组,IL-4和IL-12无显著差异。

核心结论

  • rCP01850与rPLD联合对假结核棒状杆菌攻毒提供最佳保护,并诱导更强的1型辅助T细胞免疫应答。

研究设计与样本

  • 研究在小鼠中评价假结核棒状杆菌重组蛋白rCP09720或rCP01850与重组外毒素磷脂酶D(rPLD)联合作为亚单位疫苗的效果。
  • 四个实验组每组10只小鼠:G1免疫无菌0.9%氯化钠溶液,G2免疫rPLD,G3免疫rPLD+rCP09720,G4免疫rPLD+rCP01850。
  • 小鼠间隔21天接受两剂疫苗,末次免疫后21天攻毒,攻毒后每日观察40天并记录死亡率。

主要发现

  • 首次免疫后第42天,实验组总IgG产量显著增加。
  • 第42天,G2、G3、G4组的特异性IgG2a水平高于IgG1水平。
  • G4对两种抗原均显示显著(p<.05)体液免疫应答。
  • 免疫诱导的细胞免疫应答表现为干扰素-γ产量显著(p<.05)高于对照组,而IL-4和IL-12浓度在任何组均无显著差异。
  • 肿瘤坏死因子仅在G4中观察到显著增加;攻毒后生存率分别为rPLD组30%、rPLD+rCP09720组40%、rPLD+rCP01850组50%。

关键数值与推荐

  • G4(rPLD+rCP01850)对两种抗原均产生显著(p<.05)体液免疫应答。
  • 免疫组干扰素-γ产量较对照组显著(p<.05)升高。
  • 攻毒后生存率:rPLD组30%,rPLD+rCP09720组40%,rPLD+rCP01850组50%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Caseous lymphadenitis (CLA) is a chronic disease responsible for significant economic losses in sheep and goat breeding worldwide. The treatment for this disease is not effective, and an intense vaccination schedule would be the best control strategy. In this study, we evaluated the associations of rCP09720 or rCP01850 proteins from Corynebacterium pseudotuberculosis with recombinant exotoxin phospholipase D (rPLD) as subunit vaccines in mice. Four experimental groups (10 animals each) were immunized with a sterile 0.9% saline solution (G1), rPLD (G2), rPLD + rCP09720 (G3), and rPLD + rCP01850 (G4). The mice received two doses of each vaccine at a 21-day interval and were challenged 21 days after the last immunization. The animals were evaluated daily for 40 days after the challenge, and mortality rate was recorded. The total IgG production level increased significantly in the experimental groups on day 42 after the first vaccination. Similarly, higher levels of specific IgG2a were observed in experimental groups G2, G3, and G4 compared to the IgG1 levels on day 42. G4 showed a significant (p < .05) humoral response against both antigens of the antigenic formulations. The cellular immune response induced by immunization was characterized by a significant (p < .05) production of interferon-γ compared to that in the control, while the concentrations of interleukin (IL)-4 and IL-12 were not significant in any group. A significant increase of tumor necrosis factor was observed only in G4. The survival rates after the challenge were 30% (rPLD), 40% (rPLD + rCP09720), and 50% (rPLD + rCP01850). Thus, the association of rCP01850 with rPLD resulted in the best protection against the challenge with C. pseudotuberculosis and induced a more intense type 1 T-helper cell immune response.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Silva MTO, Bezerra FSB, de Pinho RB, et al. Association of Corynebacterium pseudotuberculosis recombinant proteins rCP09720 or rCP01850 with rPLD as immunogens in caseous lymphadenitis immunoprophylaxis. Vaccine. 2017. PMID: 29174312. doi:10.1016/j.vaccine.2017.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。